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Abstract
Background: There is a need for biomarkers insuring identification of septic patients at high-risk for death. We performed a
prospective, multicenter,observational study to investigatethetime-courseof lipopolysaccharidebinding protein (LBP)serum
levels in patients with severe sepsis and examined whether serial serum levels of LBP could be used as a marker of outcome.
Methodology/Principal Findings: LBP serum levels at study entry, at 48 hours and at day-7 were measured in 180 patients
with severe sepsis. Data regarding the nature of infections, disease severity, development of acute lung injury (ALI) and
acute respiratory distress syndrome (ARDS), and intensive care unit (ICU) outcome were recorded. LBP serum levels were
similar in survivors and non-survivors at study entry (117.4675.7 mg/mL vs. 129.8671.3 mg/mL, P=0.249) but there were
significant differences at 48 hours (77.2657.0 vs. 121.2673.4 mg/mL, P,0.0001) and at day-7 (64.7645.8 vs. 89.7661.1 mg/
ml, p=0.017). At 48 hours, LBP levels were significantly higher in ARDS patients than in ALI patients (112.5671.8 mg/ml vs.
76.6655.9 mg/ml, P=0.0001). An increase of LBP levels at 48 hours was associated with higher mortality (odds ratio 3.97;
95%CI: 1.84–8.56; P,0.001).
Conclusions/Significance: Serial LBP serum measurements may offer a clinically useful biomarker for identification of
patients with severe sepsis having the worst outcomes and the highest probability of developing sepsis-induced ARDS.
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Introduction
Sepsis remains a major challenge in critical care medicine. It is
the leading cause of death and its mortality has not decreased
substantially in the past decade [1,2]. An explosion of information
regarding the inflammatory response to sepsis has prompted a
search for biomarkers that help elucidate molecular pathways that
are important in the pathogenesis of the septic process and acute
lung injury, that predict outcome, and that may serve as surrogate
indicators of potential benefits of therapies [3–8]. However, there
is not convincing evidence to support the clinical use of any
specific marker. Lipopolysaccharide binding protein (LBP), a key
participant in the inflammatory response to infection, may be a
useful marker for diagnosis and prognosis of patients with bacterial
infections [9]. LBP is a type I acute phase response protein that is
produced by hepatocytes, respiratory epithelial cells and a myriad
of other cell types [10], and enhances the recognition of endotoxin
and pathogens by the immune system [11]. LBP binds to Gram-
negative bacteria via the lipid A part of the lipopolysaccharide
(LPS) which mediates its binding to the CD14 cellular receptor
molecule presented by monocytes and macrophages [12,13].
Binding of LPS activates monocyte/macrophage system cells via
Toll-like receptors [14], resulting in the production of pro-
inflammatory cytokines that aggravate the clinical presentation of
sepsis. In humans, LBP is constitutively present at a mean serum
concentration of 5–20 mg/mL [15,16], reaching peak levels higher
than 200 mg/mL during the acute-phase reaction [5,13,17]. LBP
also mediates the immune response to diverse pathogens including
PLoS ONE | www.plosone.org 1 August 2009 | Volume 4 | Issue 8 | e6818Gram-positive bacteria [18]. Thus, several studies have reported
increased LBP serum levels in adult patients with sepsis caused by
bacterial and fungal infections [13,16–22]. However, some of
those studies have shown conflicting results and others failed to
show any correlation between blood levels and disease severity,
most likely due to the limited number of patients with severe sepsis
[13,6–22] and/or the absence of follow-up LBP measurements
[16,17,19–21].
In this study, using a large, multicenter cohort of patients
meeting the international criteria for severe sepsis, we hypothe-
sized that the pattern of LBP serum levels during the first week of
severe sepsis development is a marker of severity and prognosis.
The goals of this study were to determine: (i) whether there is a
different pattern of LBP serum levels between survivors and non-
survivors; (ii) the utility of monitoring LBP serum changes within
the first 7 days of severe sepsis as a predictor of outcome, and (iii)
whether LBP serum levels differ between patients who developed
different degrees of lung injury.
Materials and Methods
Objectives
We analyzed the time-course of LBP serum levels in patients
with severe sepsis to investigate the hypothesis that serial serum
levels of LBP could be used as a marker of severity and outcome in
patients with severe sepsis.
Ethics
The study was approved by the Ethics Committees for Clinical
Research of the Hospital Universitario NS de Candelaria in
Tenerife, Spain, and of the Hospital Universitario Rı ´o Hortega in
Valladolid, Spain. Written informed consent was obtained from
each patient or an appropriate proxy.
Participants
This multicenter, prospective, observational study included
consecutive patients older than 18 years old fulfilling the
International Sepsis Criteria for severe sepsis [23] admitted
between April 2003 and March 2006 into a network of Spanish
intensive care units (ICUs) (see appendix for a list of participating
centers). We chose to study only patients with severe sepsis to
guarantee severity of illness and a high risk for death. All patients
were screened for severe sepsis on ICU admission and daily
thereafter. Severe sepsis was defined as sepsis complicated by
organ dysfunction [23]. We considered sepsis as a clinical
syndrome defined by the presence of both infection and a systemic
inflammatory response [23,24]. Sepsis was microbiologically
documented or clinically suspected as a result of the presence of
white blood cells in a normally sterile body fluid, a perforated
viscus, chest X-ray consistent with pneumonia and associated with
purulent tracheal secretion, or other clinical syndromes associated
with a high probability of infection. Clinically documented
infection was defined by the presence of gross pus or an abscess,
but no microbiological confirmation because of ongoing antibiotic
therapy. Patients were enrolled into this study within the first
24 hours of meeting criteria for severe sepsis. Patients in whom
decisions to withhold or withdraw life sustaining treatment were
established within the first 24 hours of ICU admission, were
excluded. All patients were screened on a daily basis for the
presence of clinical and analytical signs of sepsis and, when
indicated, cultures, biopsy or aspiration of the potentially infected
sites were obtained. Patients were followed until ICU discharge or
death.
As a general approach, and for the purpose of this prospective,
observational, multicenter, cohort study, all participating physi-
cians were urged to administer broad-spectrum antimicrobial
agents in a timely manner, ensure early identification of causative
microorganism, intravenous antibiotics as soon as sepsis was
suspected or recognized, and to optimize antibiotic selection and
timely administration on the basis of the antibiogram. For the
ventilatory management, a tidal volume of 5–9 mL/kg predicted
body weight at a ventilatory rate to maintain adequate PaCO2,
and with PEEP and FiO2 combinations to maintain
PaO2.60 mmHg or SpO2.90% were recommended. Fluid
resuscitation and vasopressor administration were individualized.
The goal was to maintain a systolic blood pressure $90 mmHg or
a mean arterial pressure of $65 mmHg. It was recommended to
maintain hemoglobin between 7–10 g/dl [25]. None of the
patients in this cohort received activated protein C or low doses
of corticosteroids as an adjunctive treatment.
Data collection
All data were collected on standardized forms by the clinicians
responsible for the study in each ICU. Data collection included
demographics, diagnoses, comorbidities, source of sepsis and
isolated pathogens. Clinical and laboratory data needed to
calculate the Acute Physiology and Chronic Health Evaluation
(APACHE) II score were collected within the first 24 hours after
ICU admission [26]. All patients enrolled in the present study were
followed prospectively for the development of acute lung injury
(ALI) and acute respiratory distress syndrome (ARDS), as defined
by the American-European Consensus Conference [27]. In
addition, number of organ failures included in the Sequential
Organ Failure Assessment (SOFA) scale [28], date and time of
inclusion into the study (fulfilled the criteria for severe sepsis), ICU
and hospital length of stay, and ICU, hospital and 28-day
mortality were recorded.
Blood sampling and laboratory analyses
Blood samples (5 mL) were collected within 24 hours of meeting
severe sepsis criteria (baseline). Additional blood samples were
obtained at 48 hours and at 7 days after study entry, only if the
patient remained hospitalized into the ICU. Samples were
centrifuged at 4uC for 10 min at 3200 rpm within 35 min after
sampling. Three aliquots of serum were collected in cryovials and
frozen and stored at 280uC. Participating centers shipped the
tubes on dry ice to the research laboratory of the coordinating
center. Serum LBP was assayed using a commercially available
chemoluminescence fully automated immunoassay in an Immulite
1000 analyzer (Diagnostics Products Corporation, Siemens
Medical Solutions, Germany). As stated by the manufacturer,
the lower assay limit for the LBP assay was 0.2 mg/ml, and the
calibration ranged was up to 200 mg/ml, having a 10
3 linear
dynamic range. The described manufacturer within-run intra-
sample coefficient of variation ranged from uppermost values of
5,8% for mean concentrations of 14 mg/ml to 3.3% for a
concentration of 43 mg/ml. A dilution series was performed for
those samples with initial values above the range limit. Single LBP
serum measurements in each patient were determined by the same
investigator (MM) who was blinded to the clinical parameters and
outcome of patients.
We chose to test several markers within the inflammatory
cascade in a subset of 107 patients in whom adequate serum was
available. We measured four biomarkers that have pathogenetic
basis in sepsis and ALI/ARDS [interleukin (IL)-6, IL-1-beta, IL-
10, and C-reactive protein (CRP)] at study entry, at 48 h and at 7
days. Biomarkers levels were measured in duplicate using a
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1-beta, and IL-10 (Siemens Medical Solutions Diagnostics,
Caernarfon, UK) in an Immulite analyzer, and CRP (Roche
Diagnostic, Basilea, Switzerland) in a Hitachi 917 analyzer.
Statistical analysis
Continuous variables are described as either a mean6standard
deviation (SD), or as a median with interquartile range (IQR).
Serum levels among different groups were compared by ANOVA
or Student t-test. Categorical variables were compared using the
Pearson’s chi-square test. A logistic regression model with
backwards elimination was used to predict disease outcomes by
the variation of LBP levels at 48 hours (transformed into a simple
2 status categorical variable: increase or no-increase), adjusting for
age, gender, number of organ failures, ARDS and APACHE II
score. To compare the evolution of LBP and IL-6, IL-1-beta, IL-
10, and RCP levels during the first week, a longitudinal analysis
using a general linear model (GLIM) for repeated measures was
used to test the variation of markers levels over time within and
between groups. A Kaplan-Meier survival analysis was used to
compare 28-day survival between patients with and without LBP
increase at 48 hours of study enrollment. Finally, to validate and
compare the LBP serum levels as a possible biomarker, receiver
operator characteristic (ROC) curves and the area under the
curves (AUC) were computed to determine the sensitivity/
specificity pairs corresponding to particular LBP levels and
APACHE II scores for the discrimination between survivors and
non-survivors. Data were analyzed by using SPSS 15.0 for
windows (SPSS Inc, Chicago, IL). A two-tailed P value,0.05
was considered significant.
Results
We enrolled 180 patients with severe sepsis. Main characteristics
of the cohort are presented in Table 1. Mean age was 63.3615
years and mean APACHE II score was 23.266.8. Patients had
been hospitalized a median of 1 day (IQR: 0–7 days) prior to ICU
admission and 54.4% had severe sepsis on ICU admission.
Peritonitis was the leading cause of severe sepsis followed by
pneumonia. Blood cultures were negative in 49.5% of cases. Most
commonly isolated microorganisms were Gram-negative bacteria.
Fifty-five percent developed ARDS and 31.1% developed ALI
during hospitalization. Overall ICU mortality was 41.1% (Table 1).
The mean baseline LBP serum level was 122.5674 mg/mL
(range 26.9–334.0 mg/mL) without significant differences between
age, gender, APACHE II score or source of infection. There were
no statistical differences of LBP levels in relation to the causative
pathogens at study entry: gram-negative infections (136.1682.8),
gram-positive infections (126.4672.0 mg/ml), fungal infections
(96.5653.7 mg/ml), polymicrobial infections (135.2673.0 mg/ml)
(p=0.385); at 48 hours: gram-negative infections (91.8666.3 mg/
ml), gram-positive infections (81.7661.5 mg/ml), fungal infections
(62.9626.3 mg/ml), polymicrobial infections (105.5663.2 mg/ml)
(p=0.714); and at 7 days: gram-negative infections
(76.9645.8 mg/ml), gram-positive infections (72.7668.2 mg/ml),
fungal infections (40.4627.9 mg/ml), polymicrobial infections
(69.6649.2 mg/ml) (p=0.865).Mean LBP levels decreased at
48 hours (93.7666.8 mg/mL) and at day-7 (73.0652.4 mg/mL).
This decrease was significantly larger in patients who survived and
in those who did not develop ARDS. The largest differences in
LBP levels were found at 48 hours between patients who
developed ARDS and ALI, and between survivors and non-
survivors (P,0.0001, for both comparisons) (Table 2). Patients
developing ARDS had the highest values of LBP.
The GLIM test for repeated measures showed that LBP levels
duringthefirstweek ofseveresepsis clearlyseparated survivors from
non-survivors (P,0.013) (Figure 1). The initial sample size of 180
patients at study entry was subsequently reduced to 147 patients at
48 hoursandto100 patientsafteroneweekduetoeitherICUdeath
(16 patients at 48 h, 22 patients at day-7), ICU discharge alive (10
patients at 48 h, 26 patients at day-7) and/or non-available samples
(7 patients at 48 h, 1 patients at day-7). We noted that patients with
an ICU stay less than 48 hours had a higher mortality rate (57.6%,
19 outof33)than theremainingpatients inthestudy(37.4%, 55 out
of 147) (p=0.033). However, when patients with ,48 hours ICU
stay were compared to those with $48 hours ICU stay, there were
no significant differences with regard to age (P=0.457), gender
(P=0.205), lung injury (P=0.248), source of infection (P=0.446),
or LBP serum levels at study entry (P=0.792).
IL-6, IL-1-beta, IL-10, and CRP levels in survivors and non
survivors are summarized in Figure S1 (see supporting material). Using
the same analyses that we used for LBP, none of those 4
biomarkers showed statistically significant differences among
survivors and non-survivors across days examined. Furthermore,
since the sample size of the subset of patients in whom we
measured these additional markers was smaller (107 vs. 180 for
LBP), for each of these markers we generated a simulated 180
patient dataset increasing artificially their sample size by adding
measures from 73 randomly selected cases by resampling. Despite
this correction, no statistical significant differences were found
between survivors and non-survivors. For IL-6 (the marker with
best significance level), the significance levels were p=0.281 at
study entry, p=0.347 at 48 hours, and p=0.082 at 7 days.
ROC curves and AUC (Figure 2) showed that LBP serum levels
at 48 hours were a better predictor of outcome than the APACHE
II score calculated within the first 24 h after ICU admission. The
significance for APACHE II was P=0.016 (AUC: 0.62; 95% CI:
0.52–0.71), for LBP at study entry was P=0.173 (AUC: 0.57; 95%
CI: 0.47–0.66) and for LBP at 48 hours was P,0.0001 (AUC:
0.71; 95%CI: 0.61–0.80).
We noted that in 39 patients, LBP serum levels increased at
48 hours compared to baseline (mean increase 49.7 mg/mL) and
their mortality was significantly higher than in the 108 patients in
whom LBP decreased (mean decrease 252.9 mg/ml) [mortality
61.5% vs. 28.7%, respectively; odds ratio (OR) 3.97; 95% CI:
1.85–8.57, P,0.001] (Figure 3). Even after adjusting for age,
gender, number of failing organs, and APACHE II score, an
increase of LBP at 48 hours continued to predict a higher
mortality risk (adjusted OR: 2.76; 95% CI: 1.16–6.54,
P=0.018).Kaplan-Meier 28-day survival curves showed strong
significant differences between patients with or without increases
in LBP levels at 48 hours (log rank test, P=0.0001) (Figure 4).
Discussion
The main finding of this study is that changes in LBP serum
levels at 48 hours after the onset of severe sepsis were associated
with disease severity and outcome. Our findings indicate that serial
LBP serum measurements may offer a clinically useful biomarker
for identification of patients, with severe sepsis, having the worst
outcomes and the highest probability of developing sepsis-induced
ARDS. In our study, as well as in previous studies [13,22], serum
LBP levels did not differ among patients with gram-negative,
gram-positive or fungal infections. The mean LBP serum levels in
our series are within the same range as in previous reports
[13,19,22,29–31].
Blairon et al [20] measured LBP serum levels daily until day 5
or death in a small sample of 24 patients with severe sepsis, but
LBP in Severe Sepsis and ARDS
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levels and severity, as defined by APACHE II, lung injury and
multiple organ dysfunction scores. Prucha et al [13] assessed LBP
levels at study entry and at 3- to 5-day intervals for 30 days or until
death in a mixed population of 68 patients with systemic
inflammatory response, sepsis or septic shock. However, they did
not find significant differences in LBP levels between patients with
systemic inflammatory response and sepsis or between survivors
and non-survivors, since only 9 patients had severe sepsis and/or
septic shock. Sakr et al [22] measured the time course of LBP
levels in a mixed sample of 327 critically ill patients in which only
55 patients had severe sepsis. As in other previous studies with
limited number of patients [13,16,30], they found that during the
first two days of the disease process LBP concentrations were
higher in patients with severe sepsis than in those without sepsis,
although no further differences between these groups of patients
were observed after the second day. Additionally, Sakr et al [22]
concluded that the maximum LBP serum concentration during the
first 3 days in the ICU discriminated between survivors and non-
survivors, but they were unable to determine if such levels could
discriminate between survivors and non survivors among patients
with severe sepsis because of the limited sample size (n=55).
The study by Opal et al [17] is the only published report with a
sample size comparable to our study. They measured LBP plasma
levels in 253 patients with severe sepsis and/or septic shock and
reported mean LBP levels in the lower range of those not only in
our series but also in other recent reports [13,22,29]. They found
that LBP levels were less elevated in non-survivors than survivors.
Although the mean APACHE II score in their series was similar to
our series, the mortality of their cohort was lower (32.4%) than in
our series or that reported in recent epidemiological studies [2,32–
35]. Several differences could explain the discrepancies between
Table 1. Main characteristics of 180 patients with severe sepsis.
Variable Patients (N=180)
Gender, male/female (%) 59/41
Age (mean6SD) 63615
Severity (mean6SD)
APACHE II score 23.266.8
SOFA score 9.763.3
Number of organ failures 2.361.3
White blood cells at study entry, 10
3 cells/mL 16,869,6
ICU admission
Days between hospital and ICU admission, median (p25,p 75) 1 (0–7)
Days between ICU admission and severe sepsis criteria, mean6SD 1.663.1
Median ICU stay, days (p25,p 75) 7 (3–17)
Identified Pathogen (%)
Positive blood cultures 50.5
Gram-negative only 25.0
Gram-positive only 15.0
Fungi only 2.8
Polymicrobial 7.8
Source of infection (%)
Gastro-intestinal tract 47.8
Respiratory tract 36.1
Bone and soft tissue 8.9
Genitourinary tract 4.4
Catheter related 2.8
Comorbid conditions (%)
Insulin-dependent diabetes 7.8
Immunosuppression 10.0
Lung injury (%)
ARDS 55
ALI 31
Outcome (%)
28-day mortality 40.5
ICU mortality 41.1
Hospital mortality 46.7
APACHE: Acute Physiology and Chronic Health Evaluation; SOFA: sequential organ failure assessment; ICU: intensive care unit; ARDS: acute respiratory distress
syndrome; ALI: acute lung injury.
doi:10.1371/journal.pone.0006818.t001
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analysis of a population of septic patients selected from the placebo
arm of a phase III randomized controlled trial to define the safety
and efficacy of recombinant human interleukin 1 receptor
antagonist in patients with sepsis [36]. Second, it is plausible that
a selection bias occurred since the strict inclusion and exclusion
criteria would select patients who were more likely to benefit by
the drug under investigation. The observational and non-
therapeutic nature of our study design allowed the inclusion of
all consecutive patients meeting the criteria for severe sepsis with
virtually no exclusion criteria, and therefore, we believe that our
patients more closely represent those patients with severe sepsis
managed in a routine ICU [35]. The later would explain why our
patient population was sicker than the Opal et al. Third, the
placebo (control) group in the parent paper by Fisher et al [36]
consisted of 302 patients, from which (according to Table 4 in
their paper) only 187 patients (62%) had dysfunction of one or
more organs, a necessary criteria for being diagnosed as having
severe sepsis. However, Opal et al included 253 patients out of
those 302 (84%) as having severe sepsis. Forth, although the mean
APACHE II score in the Opal et al study was apparently similar to
our cohort (26 vs. 23), the magnitude of the standard deviations in
both studies (13.6 vs. 6.8, respectively) showed more heterogeneity
in their patient population than in our cohort (p=0.005). Fifth, we
do not have much information regarding the prevalence of acute
respiratory failure and the use of mechanical ventilation in the
Opal study. They reported that 27% of patients had ARDS
whereas in our patient population, all patients were mechanically
ventilated and 55% had ARDS. We are not surprised by the high
prevalence of acute lung dysfunction in our series of severe sepsis
since sepsis is the most common clinical condition associated with
the development of ARDS and this relationship increases with
sepsis severity. In addition, it has been reported that in more than
half of patients with severe sepsis without ARDS there is an
increased extravascular lung water content, representing subclin-
ical and clinical lung injury [37]. Lastly, there is no enough
information on how LBP assays were performed in the Opal et al
paper to allow a comparison with our study. Since the data and
blood sample collection in the two studies are separated by 15
years, we should acknowledge that differences in patient care, ICU
Table 2. LBP serum levels among patients with different degrees of lung injury and in ICU survivors and non-survivors.
Condition Outcome Baseline (N=180) 48 h (N=147) 7th Day (N=100)
Lung Injury ARDS (N=99) 132.5676.5 112.5671.8 79.3656.1
ALI (N=56) 116.4672.2 76.6655.9 68.8646.9
non ALI/ARDS (N=25) 96.7661.9 51.9630.5 43.0626.4
P-value* 0.106 ,0.0001 0.076
ICU Survival Survivors (N=106) 117.4675.7 77.2657.0 64.7645.8
Non-survivors (N=74) 129.8671.3 121.2673.4 89.7661.1
P-value{ 0.249 ,0.0001 0.017
Values are expressed as mean6SD in mg/mL. LBP: lipopolysaccharide binding protein; ARDS: acute respiratory distress syndrome; ALI: acute lung injury; ICU: intensive
care unit.
*P- value from one way ANOVA.
{P- value from t-test.
doi:10.1371/journal.pone.0006818.t002
Figure 1. LBP serum levels in 180 patients with severe sepsis
during the first week in the ICU. Data are reported as mean (6SE).
LPB: lipopolysaccharide-binding protein; ICU: intensive care unit. P-
value was obtained using a general linear model.
doi:10.1371/journal.pone.0006818.g001
Figure 2. Receiver operator characteristic (ROC) curves for
discriminating survivors from non-survivors. Curves were ob-
tained according to lipopolysaccharide-binding protein (LBP) serum
levels at study entry and at 48 h. ROC results using APACHE II scores on
the day of ICU admission are also plotted for comparison. APACHE:
Acute Physiology and Chronic Health Evaluation; ICU: intensive care
unit.
doi:10.1371/journal.pone.0006818.g002
LBP in Severe Sepsis and ARDS
PLoS ONE | www.plosone.org 5 August 2009 | Volume 4 | Issue 8 | e6818admission policies, the nature of the patient mix, the use of
retrospective analysis of data, methods of blood collection and
shipping and the technology for LBP assays could explain
discrepancies in the reported LBP values.
Our study is the first to report an association between LBP levels
and severity of respiratory dysfunction and between LBP levels
and outcome in patients with sepsis-induced ARDS. Only 19
ARDS patients were diagnosed during the first 48-hour of study
entry; the rest were diagnosed later during ICU hospitalization.
Thus, in most cases, the worsening of pulmonary dysfunction
followed LBP increase. Martin et al [31] measured LBP
concentrations in the bronchoalveolar lavage fluid (BAL) of 82
patients with ARDS. Although they found that LBP increased
markedly in the BAL, LBP values were similar in all subgroups of
patients and were not related to survival. Cunningham et al [38]
assessed time-dependent changes in LBP serum concentrations in
121 trauma patients on hospital admission and at 24 h. In this very
low-mortality group (16.3%), a significant increase in LBP
concentration was observed at 24 h (28.0625.3
vs.72.3645.7 mg/mL). However, although baseline LBP levels
were significantly greater in non-survivors than in survivors, after
controlling for age and disease severity, LBP concentration did not
predict survival. The major difference between those studies
[31,38] and ours is that they measured LBP levels within the first
24 h of admission to the ICU in a heterogeneous population of
patients, whereas we performed serial measurements in a
population of patients with the same clinical condition (severe
sepsis).
In general, our findings and those from other previous reports
[13,16,17,19–22,29,30,38] support the important role that LBP
plays in host-defense during sepsis. In the current study, the
variation of LBP concentrations at 48 h predicted worsening acute
lung injury and death. We postulate that changes in biomarker
levels during the course of severe sepsis may enable physicians to
identify those patients who are most at risk for deterioration and
who are in greatest need of early intervention. A close examination
of changes in LBP serum levels at 48 h and their correlation with
outcome enabled us to identify a subgroup of 39 patients (21.7%)
in which significantly worse outcomes were observed. In those
patients, rather than decreasing LBP levels at 48 h, as expected,
the serum concentrations were higher than at onset [Note that
these increments were not small (median: 49.7 mg/mL; IQR:
15.1–63.3 mg/mL)]. We cannot explain this finding but can
speculate why these patients progressed toward a fatal outcome.
During sepsis, LBP levels are modified by polymorphic genetic
variation of the LBP gene [3,39–41], predisposing these patients to
excessive inflammation during an infection and contributing to a
poor outcome. Chien et al [41] have recently reported that the
presence of a common variant in the 59 flanking region of the LBP
gene was correlated with basal LBP serum levels in healthy
controls and mortality in patients after allogeneic hematopoietic
cell transplantation.
In our study, the changes in the systemic levels of IL-6, IL-1-
beta, IL-10, and CRP were unable to discriminate survivors from
non survivors during the first week of severe sepsis. In addition,
LBP levels at 48 h performed better than APACHE II in
predicting ICU outcome. The ROC curve showed that LBP at
48 h dominates APACHE II for any given sensitivity or specificity
threshold. The APACHE II requires collection of data regarding
Figure 3. Percentage of survivors and non-survivors patients with severe sepsis according to changes in LBP levels after 48 h of
enrolment. LPB: lipopolysaccharide-binding protein. P-value was obtained using chi-square test.
doi:10.1371/journal.pone.0006818.g003
Figure 4. Kaplan-Meier curves for 28-day survival analysis of
patients with severe sepsis. In continuous line, patients in which
lipopolysaccharide-binding protein (LBP) serum levels increased at 48 h;
in discontinuous line, patients in which LBP did not increase at 48 h.
doi:10.1371/journal.pone.0006818.g004
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of ICU admission) taking into account the most abnormal values,
relies on laboratory data that may be not uniformly collected, and
its use is limited by significant inter- and intraobserver variability
[42]. It has been reported that several factors influence the
performance of severity of illness scoring system: lead time bias
[43], case mix, pre-ICU or ICU management, sampling rate of
laboratory and hemodynamic data [44], and novel advances in
ICU care and therapy since scoring systems were described [26].
On the other hand, it is important to emphasize that the APACHE
II score was developed to predict mortality in general ICU
population using data during the first 24 hours of ICU stay. On
average, patients from our study met severe sepsis criteria almost 2
days after ICU admission and we did not calculate APACHE II at
the time patients met criteria for severe sepsis since it is unknown
whether the use of APACHE scores generated at the time of
patient enrolment result in under or over performance of
APACHE II. We speculate that the main reason behind APACHE
II not being a good predictor in severe sepsis could be due to
APACHE II is a general purpose severity of disease classification
system while LBP serum levels might have a more specific
association with severe sepsis. Since APACHE II includes many
physiological measurements that are not related with sepsis, it is
plausible that it does not perform as well on a cohort of patients
with severe sepsis in whom the main cause of death (multiple
organ dysfunction) is attributed mainly to one factor (severe
infection).
It is unlikely that the multifaceted nature of severe sepsis or
ARDS would be only monitored with the use of a single
biomarker. Microarray-based genome-wide gene expression
analysis have shown in animal models that the induction of
systemic inflammation by sepsis can cause synergistic effects with
acute lung injury in the setting of mechanical ventilation,
suggesting that molecules related to the innate immune pathway
recognizing the endotoxin might be regulated as well in the
presence of lung injury in the absence of infection [45–47]. In a
recent metaanalysis, Wurfel [48] has indicated that across the
different experiments, the most clearly overrepresented theme was
‘‘responses to pathogens’’, noting that the selected genes for the
final analyses were identified as differentially regulated in the
presence of injury by mechanical ventilation alone. Given this
evidence, and since our study have not been designed to answer
the question of whether the LBP response is specific or typical of
many acute phase proteins, we suggest that the response is, most
likely, non-specific.
There are some limitations to our study. First, confirmatory
studies with large sample sizes are required to validate this study.
Second, despite the fact that changes in mean LBP levels
discriminated survivors from non-survivors, our findings cannot
define a cut-off point to clearly identify septic patients at 48 h who
will survive from those who will not survive, nor clearly identify
septic patients who will develop ARDS from those who will not
develop it. Third, a drop off in the number of patients at 48 h
(from 180 to 147) could affect the overall significance. However,
we do not think that this event would have a major effect on the
utility of LBP levels as a prognostic biomarker. It is plausible that
those who died within the first 48 h had higher levels of serum
LBP in the hours that preceded death, making the overall
significance even greater if those values were considered at 48 h.
Forth, different therapeutic regimes could influence the LBP
values and their associated outcome. However, since it was beyond
the scope of this study, we do not know whether treatment-
dependent variables may influence the performance of our model
under different practice patterns. None of the patients in this
cohort received activated protein C or low doses of corticosteroids
as an adjunctive treatment. As Kalil et al have recently evaluated
[49], the strength of statistical and clinical evidence is weak for
most clinical trials on therapies that have been recommended in
recent guidelines for treating patients with severe sepsis,
particularly for low dose steroids, recombinant human activated
protein C, and early goal-directed therapy. Those authors have
stated that it is essential to replicate those trials in confirmatory
studies before guidelines can be fully adopted by clinicians. In fact,
a new PROWESS trial is currently underway to test (and validate)
the effects of activated protein C in a high risk septic population.
Our findings add additional justification for evaluating LBP in
various high-risk populations during clinical trials. As Minter et al
[50] have recently suggested, biomarkers may ultimately serve as
targets for future therapeutic trials in severe sepsis whereas it seems
essential to choose a biomarker defining appropriate high-risk
populations in whom the initial immune inflammatory response is
amplified beyond the threshold that is tolerated by the host. Serial
monitoring of LBP serum levels may be an appropriate biomarker
for subgroup selection and guiding of therapy. We also anticipate
that pharmacologic modulation of LBP activation may represent a
novel target for future therapeutic trials in the setting of severe
sepsis.
In summary, the current study constitutes a step forward over
previous published studies investigating the potential use of LBP as
a biomarker in sepsis. We have found that a distinct pattern of
elevated serum levels of LBP in patients with severe sepsis is
strongly associated with increased mortality and the development
of ARDS. Additional study is necessary, however, before this or
any biomarker can be used to predict outcome in severe sepsis.
Supporting Information
Figure S1 Comparison of serum levels of IL-6, IL-1-beta, IL-10,
and CRP in 107 patients with severe sepsis during the first week in
ICU. Data are reported as mean (6SE). IL: interleukin; CRP: C-
reactive protein; ICU: intensive care unit. P-value was obtained
using GLIM.
Found at: doi:10.1371/journal.pone.0006818.s001 (0.49 MB TIF)
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